Central neurologic involvement in mycosis fungoides: Ten cases, actuarial risk assessment, and predictive factors

Cancer Journal

Volumn 12, Issue 1, 2006, Pages 55-62

  Stein, Moshe ^a   Farrar, Nathan ^b   Jones, Glenn W ^b   Wilson, Lynn D ^c   Fox, Lisa ^b   Wong, Raimond K ^d   Kuten, Abrahem ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CREDIT VALLEY HOSPITAL   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Central nervous system; Lymphoma; Mycosis fungoides

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; PSORALEN; STEROID;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; LABORATORY TEST; MALE; MYCOSIS FUNGOIDES; NEUROLOGIC DISEASE; NEUTROPENIA; PHYSICAL EXAMINATION; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PUVA; RISK ASSESSMENT; TOTAL SKIN ELECTRON THERAPY; VISCERAL METASTASIS;

ACTUARIAL ANALYSIS; ADULT; AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; FATAL OUTCOME; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SKIN NEOPLASMS;

EID: 33645853457     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200601000-00010     Document Type: Article

References (27)

1. Wilson LD, Jones GW, Edelson RL et al. Cutaneous T-cell lymphomas. In: DeVita VT, Helman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2004.
2. Jones G, Wilson LD, Fox-Goguen L. Total skin electron beam radiotherapy for patients who have mycosis fungoides. Hematol Oncol Clin North Am 2003;17:1421-1434.
3. de Coninck EC, Kim YH, Varghese A et al. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001;19:779-784.
4. Carney DN, Bunn PA. Manifestations of cutaneous T-cell lymphoma. J Dermatol Surg Oncol 1980;6:369-377.
5. Hagedorn M, Freudenberg N, Petres J. Mycosis fungoides with marked brain involvement - a case report. Arch Dermatol Forsch 1975;252:179-186.
6. Li N, Kim JH, Glusac EJ. Brainstem involvement by mycosis fungoides in a patient with large-cell transformation: a case report and review of literature. J Cutan Pathol 2003;30:326-331.
7. Hallahan D, Griem M, Griem S et al. Mycosis fungoides involving the central nervous system. J Clin Oncol 1986;4:1638-1644.
8. Zackheim HS, Lebo CF, Wasserstein P et al. Mycosis fungoides of the mastoid, middle ear, and CNS. Literature review of mycosis fungoides of the CNS. Arch Dermatol 1983;119:311-318.
9. Kaufman DK, Habermann TM, Kurtin PJ et al. Neurological complications of peripheral and cutaneous T-cell lymphomas. Ann Neurol 1994;36:625-629.
10. Jones GW, Kacinski BM, Wilson LD et al. Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002;47:364-370.
11. Anacak Y, Arican Z, Drumea K et al. Total skin electron irradiation in mycosis fungoides: comparison between modified Christie Hospital translocational technique and the Stanford technique. Leuk Lymphoma 2002;43:2093-2097.
12. Jones GW, Tadros A, Hodson DI er al. Prognosis of newly diagnosed mycosis fungoides after total skin radiation of 30 or 35 GY. Int J Radiat Oncol Biol Phys 1994;28:839-845.
13. Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1057-1076.
14. Tien RD, Brown M, Massey EW. CNS mycosis fungoides: CT and MR findings. J Comput Assist Tomogr 1992;16:529-533.
15. del Carpio-O'Donovan R, Freeman C. Brainstem involvement with mycosis fungoides: An unusual central nervous system complication. Am J Neuroradiol 2002;23:533-534.
16. Jones G. Quality of life and long-term outcomes for 955 patients with mycosis fungoides managed by the Canadian Cooperative MF study group. Presented at the Annual Clinical Meeting of the Cutaneous Lymphoma Group of the EORTC; September 26, 2004, Madrid, Spain.
17. Demierre MF, Kim YH, Zackheim HS. Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003;17:1485-1507.
18. Perea G, Altes A, Montoto S et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 2005;16:1508-1513.
19. A predictive model for aggressive non-Hodgkin's lymphoma. The International non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 2003;329:987-994.
20. Montoto S, Lister TA. Secondary central nervous system lymphoma: risk factors and prophylaxis. Hematol Oncol Clin North Am 2005;19:751-763.
21. Hollender A, Kvaloy S, Nome O et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002;13:1099-1107.
22. Ward JH, Kjeldsberg CR. Spinal cord compression in mycosis fungoides. Cancer 1982;50:2510-2512.
23. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005;26:485-495.
24. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003;3:569-581.
25. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004;4:211-222.
26. Armitage JO, Mauch PM, Harris NL et al. Non-Hodgkin's lymphomas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001.
27. Kim CH. The greater chemotactic network for lymphocyte trafficking: chemokines and beyond. Curr Opin Hematol 2005;12:298-304.